MCID: SQM013
MIFTS: 70

Squamous Cell Carcinoma, Head and Neck malady

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

About this section

Aliases & Descriptions for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 51 12
Squamous Cell Carcinoma of the Head and Neck 34 11 47 25 69 13 67
Head and Neck Squamous Cell Carcinoma 11 47 25 53 13
Hnscc 47 25 53 69 49
Carcinoma, Squamous Cell of Head and Neck 47 38
Squamous Cell Carcinoma of Head and Neck 53 26
 
Head and Neck Cancer 47 37
Squamous Cell Carcinoma, Head and Neck, Somatic 51
Squamous Cell Carcinomas of Head and Neck 11
Carcinoma of the Head and Neck 11
Cancer of Head and Neck 67
Scchn 25

Characteristics:

Orphanet epidemiological data:

53
head and neck squamous cell carcinoma:
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages

HPO:

63
squamous cell carcinoma, head and neck:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM51 275355
Disease Ontology11 DOID:5520
NCIt44 C34447
Orphanet53 ORPHA67037
MESH via Orphanet39 C535575
UMLS via Orphanet68 C1168401
MedGen36 C1168401

Summaries for Squamous Cell Carcinoma, Head and Neck

About this section
MedlinePlus:37 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. most begin in the moist tissues that line the mouth, nose, and throat. symptoms include a lump or sore that does not heal a sore throat that does not go away trouble swallowing a change or hoarseness in the voice head and neck cancers are twice as common in men. using tobacco or alcohol increases your risk. in fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. infection with hpv is a risk factor for some head and neck cancers. to diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. you will have a biopsy, where a sample of tissue is taken out and examined under a microscope. it is the only test that can tell for sure if you have cancer. if found early, these cancers are often curable. treatments may include surgery, radiation therapy, chemotherapy, or a combination. treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. nih: national cancer institute

MalaCards based summary: Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to herpes simplex and nasopharyngeal carcinoma, and has symptoms including squamous cell carcinoma, coughing and halitosis. An important gene associated with Squamous Cell Carcinoma, Head and Neck is PTEN (Phosphatase And Tensin Homolog), and among its related pathways are Immune response_Oncostatin M signaling via JAK-Stat in human cells and Thyroid cancer. Affiliated tissues include lung, thyroid and skin, and related mouse phenotypes are liver/biliary system and embryo.

Disease Ontology:11 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference:25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

NIH Rare Diseases:47 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments. Last updated: 8/3/2015

UniProtKB/Swiss-Prot:69 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Description from OMIM:51 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

About this section

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 196)
idRelated DiseaseScoreTop Affiliating Genes
1herpes simplex31.2CDKN2A, EGFR, TP53
2nasopharyngeal carcinoma31.1CDKN2A, EGFR, PIK3CA, PTEN, TP53
3adenoid squamous cell carcinoma30.6CDKN2A, TP53
4breast cancer30.4CCND1, CD44, CDH1, CTTN, EGFR, ING1
5colorectal cancer30.4CCND1, CD44, CDH1, CDKN2A, EGFR, MMP2
6esophageal cancer30.3CCND1, CD44, CDH1, CDKN2A, EGFR, MMP2
7prostate cancer30.3CCND1, CD44, CDH1, EGFR, MMP2, MMP9
8lung cancer30.2CCND1, CD44, CDH1, CDKN2A, EGFR, MMP2
9oral cancer11.1
10thyroid cancer11.1
11intraductal papilloma11.0CD44, EGFR, ING3
12uterine corpus epithelioid leiomyosarcoma11.0EGFR, PTEN, TP53
13cholesteatoma11.0CCND1, CDKN2A, STAT3
14esophagus verrucous carcinoma11.0CDKN2A, PTEN, TP53
15adenosquamous pancreas carcinoma10.9CD44, CDKN2A, EGFR
16pseudoangiomatous stromal hyperplasia10.9PIK3CA, TP53
17tamoxifen-related endometrial lesion10.9EGFR, PIK3CA, TP53
18salivary gland adenoid cystic carcinoma10.9CDKN2A, TP53
19bladder verrucous squamous cell carcinoma10.9CCND1, CDKN2A, TP53
20amelogenesis imperfecta hypomaturation type10.9STAT3, TNFRSF10B, VEGFA
21anal squamous cell carcinoma10.9CDKN2A, EGFR, TP53
22non-congenital cyst of kidney10.9CDKN2A, EGFR, PTEN
23oligodendroglioma10.9CCND1, CDKN2A, TP53
24renal pelvis carcinoma10.9EGFR, MMP2, MMP9
25skeletal tuberculosis10.9CCND1, CDKN2A
26phalanx chondroma10.9CDKN2A, MMP9, STAT3
27biliary papillomatosis10.9CDKN2A, TP53
28early myoclonic encephalopathy10.9CDKN2A, EGFR, PTEN, TP53
29novak syndrome10.9CCND1, EGFR, TP53
30peptic ulcer disease10.9EGFR, TP53
31actinic keratosis10.9CDKN2A, EGFR, TP53
32oral tuberculosis10.9CDH1, TP53
33epithelioid trophoblastic tumor10.9CDKN2A, TP53, VEGFA
34grade iii astrocytoma10.9CDKN2A, EGFR, TP53
35distal monosomy 9p10.9EGFR, TP53, VEGFA
36leukoencephalopathy palmoplantar keratoderma10.9CCND1, CD44, CDKN2A
37kidney sarcoma10.9PIK3CA, TP53, VEGFA
38ovarian small cell carcinoma10.9EGFR, PIK3CA, TP53
39calcaneonavicular coalition10.9EGFR, PIK3CA, VEGFA
40compartment syndrome10.9CD44, CDKN2A, PTEN, TP53
41emphysematous cholecystitis10.9MMP2, MMP9, VEGFA
42fallopian tube mucinous adenocarcinoma10.9CDKN2A, EGFR, TP53
43spindle epithelial tumor with thymus-like differentiation tumor10.9CDKN2A, MMP2, MMP9
44interstitial myocarditis10.9PIK3CA, PTEN
45renal tubular acidosis, distal, autosomal recessive10.9CDKN2A, EGFR, PTEN
46complex lethal osteochondrodysplasia10.9CCND1, CDH1, PIK3CA
47karak syndrome10.9CDKN2A, PTEN
48angiokeratoma circumscriptum10.9CDKN2A, EGFR, TP53
49prostate adenoid cystic carcinoma10.9CCND1, CTTN, EGFR, VEGFA
50pelvic muscle wasting10.9CDKN2A, PIK3CA, PTEN, TP53

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to squamous cell carcinoma, head and neck

Symptoms for Squamous Cell Carcinoma, Head and Neck

About this section

Symptoms by clinical synopsis from OMIM:

275355

Clinical features from OMIM:

275355

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

 63
id Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma63 HP:0002860

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


coughing, halitosis, snoring, sore throat, vertigo/dizziness, equilibration disorder

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Erbitux16 43 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
FDA Label: Erbitux
Disease/s that Drug Treats:Colorectal Cancer
Indications and Usage:16 Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicatedfor treatment of:Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the headand neck in combination with radiation therapy. (1.1, 14.1) Recurrent locoregional disease or metastatic squamous cell carcinomaof the head and neck in combination with platinum-based therapy with5-FU. (1.1, 14.1) Recurrent or metastatic squamous cell carcinoma of the head and neckprogressing after platinum-based therapy. (1.1, 14.1)Colorectal CancerK-Ras wild-type, EGFR-expressing, metastatic colorectal cancer asdetermined by FDA-approved tests in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory toirinotecan-based chemotherapy, as a single agent in patients who have failed oxaliplatin- andirinotecan-based chemotherapy or who are intolerant to irinotecan.(1.2, 5.7, 12.1, 14.2)Limitation of Use: Erbitux is not indicated for treatment of Ras-mutantcolorectal cancer. (5.7, 14.2)
DrugBank Targets:14 1. Epidermal growth factor receptor;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembraneglycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelialtissues, including the skin and hair follicle. Expression of EGFR is also detected in many humancancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitivelyinhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforminggrowth factor-alpha. In vitro assays and in vivo animal studies have shown that binding ofcetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,resulting in inhibition of cell growth, induction of apoptosis, and decreased matrixmetalloproteinase and vascular endothelial growth factor production. Signal transduction throughthe EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somaticmutations, the resulting mutant Ras proteins are continuously active regardless of EGFRregulation.In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certainhuman tumor types. In vitro assays and in vivo animal studies have shown that cetuximabinhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects ofcetuximab were observed in human tumor xenografts lacking EGFR expression. The addition ofcetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resultedin an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
2
Ethyol16 AMIFOSTINE Alza December 8, 1995
FDA Label: Ethyol
Disease/s that Drug Treats:ovarian cancer
Indications and Usage:16 ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated withrepeated administration of cisplatin in patients with advanced ovarian cancer.ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patientsundergoing post-operative radiation treatment for head and neck cancer, where the radiationport includes a substantial portion of the parotid glands (see Clinical Studies).For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin basedchemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limiteddata on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.ETHYOL should not be administered to patients in other settings where chemotherapy can produce asignificant survival benefit or cure, or in patients receiving definitive radiotherapy, except in thecontext of a clinical study (see WARNINGS).
DrugBank Targets:14 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;2. Alkaline phosphatase, placental-like
Mechanism of Action:16 
Target: -
Action: -
FDA: -
3
Taxotere16 43 DOCETAXEL Rhone Poulenc Rorer May 1996
FDA Label: Taxotere
Disease/s that Drug Treats:breast cancer
Indications and Usage:16 TAXOTERE is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BCafter chemotherapy failure; and with doxorubicin andcyclophosphamide as adjuvant treatment of operable node-positive BC(1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locallyadvanced or metastatic NSCLC after platinum therapy failure; andwith cisplatin for unresectable, locally advanced or metastaticuntreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone inandrogen independent (hormone refractory) metastatic prostate cancer(1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil foruntreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):with cisplatin and fluorouracil for induction treatment of locallyadvanced SCCHN (1.5)
DrugBank Targets:14 1. Tubulin beta-1 chain;2. Apoptosis regulator Bcl-2;3. Microtubule-associated protein 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein tau;6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:16 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that isessential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes theassembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Thisleads to the production of microtubule bundles without normal function and to the stabilization ofmicrotubules, which results in the inhibition of mitosis in cells. Docetaxel’s binding to microtubulesdoes not alter the number of protofilaments in the bound microtubules, a feature which differs from mostspindle poisons currently in clinical use.

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 478)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CetuximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1737205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
2
EthanolapprovedPhase 4, Phase 1204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
3
Gefitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1351184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
4
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
5
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
6
CevimelineapprovedPhase 4, Phase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
7Titanium dioxideapprovedPhase 43713463-67-7
8
PetrolatumapprovedPhase 4898009-03-8
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum base
Petrolatum, white
 
Petrolatum,amber
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
9
Morphineapproved, investigationalPhase 496057-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
10
Fentanylapproved, illicit, investigational, vet_approvedPhase 4773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
11
Docetaxelapproved, investigational, Approved May 1996Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 11918114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
12Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14855
13Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 110355
14Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15674
15AnalgesicsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 111287
16Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17793
17Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
18Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17171
19Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122776
20Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Early Phase 117734
21Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
22Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 14694
23Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
24Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15498
25AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111774
26Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
27Cholinergic AgentsPhase 4, Phase 33846
28AnestheticsPhase 4, Phase 3, Phase 29001
29Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13612
30Central Nervous System DepressantsPhase 4, Phase 2, Early Phase 112806
31MitomycinsPhase 4, Phase 3, Phase 2233
32NarcoticsPhase 4, Phase 23486
33Adjuvants, AnesthesiaPhase 41588
34mometasone furoatePhase 416883919-23-7
35Anti-Allergic AgentsPhase 41490
36Anesthetics, IntravenousPhase 42406
37Analgesics, OpioidPhase 4, Phase 23091
38Anesthetics, GeneralPhase 42787
39arginineNutraceuticalPhase 4, Phase 2, Phase 1408
40Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 2969
41
LenograstimapprovedPhase 3, Phase 2, Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
42
CarboplatinapprovedPhase 3, Phase 2, Phase 1, Early Phase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
43
Capecitabineapproved, investigationalPhase 2, Phase 3, Phase 11296154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
44
CitalopramapprovedPhase 350359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
45
Aspirinapproved, vet_approvedPhase 3, Phase 2111250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoic acid
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide 2-(acetyloxy)benzoique
Acide acetylsalicylique
Acide acétylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
 
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
ácido acetilsalicílico
46
Paclitaxelapproved, vet_approvedPhase 3, Phase 2, Phase 1275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
47
AldesleukinapprovedPhase 3, Phase 2, Phase 139785898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
48
Irinotecanapproved, investigationalPhase 3, Phase 2, Phase 1108097682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
49
Oxaliplatinapproved, investigationalPhase 2, Phase 3, Phase 1141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
50
MethotrexateapprovedPhase 3, Phase 2, Phase 115181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall

Interventional clinical trials:

(show top 50)    (show all 1363)
idNameStatusNCT IDPhase
1Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)Unknown statusNCT01553032Phase 4
2A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaUnknown statusNCT00642239Phase 4
3Post-marketing Surveillance Study of Docetaxel-Based ChemotherapyCompletedNCT02972216Phase 4
4Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx CarcinomaCompletedNCT00772681Phase 4
5Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced XerostomiaCompletedNCT00466388Phase 4
6Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
7A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer PatientsCompletedNCT01283906Phase 4
8Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckRecruitingNCT02015650Phase 4
9Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' PatientsRecruitingNCT02495064Phase 4
10Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyRecruitingNCT02869321Phase 4
11An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and NeckActive, not recruitingNCT00684385Phase 4
12Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
13S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
14Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
15Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateUnknown statusNCT00041613Phase 3
16Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneUnknown statusNCT00041626Phase 3
17Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.Unknown statusNCT01124409Phase 3
18Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
19Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth CancerUnknown statusNCT00002747Phase 3
20Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397Unknown statusNCT01466244Phase 3
21Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
22Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or HypopharynxUnknown statusNCT00003627Phase 3
23Topical Imiquimod for Bowen's Disease of the Head and NeckUnknown statusNCT00384124Phase 2, Phase 3
24PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
25Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the NasopharynxUnknown statusNCT00003637Phase 3
26Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced XerostomiaUnknown statusNCT00081029Phase 3
27Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea PolyphenolsUnknown statusNCT01496521Phase 3
28Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyUnknown statusNCT01402180Phase 2, Phase 3
29Elective or Prophylactic Nodal Irradiation for Esophageal CancerUnknown statusNCT01551589Phase 3
30Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIALUnknown statusNCT01039298Phase 3
31Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusUnknown statusNCT00002884Phase 3
32Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal CancerUnknown statusNCT00509561Phase 2, Phase 3
33Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and NeckCompletedNCT00442455Phase 3
34Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese SubjectsCompletedNCT01012258Phase 3
35Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)CompletedNCT00206219Phase 3
36Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT01086826Phase 3
37A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and NeckCompletedNCT01177956Phase 3
38Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)CompletedNCT00122460Phase 3
39Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
40DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedNCT00496652Phase 3
41Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00401323Phase 2, Phase 3
42Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00460265Phase 3
43Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCompletedNCT01166542Phase 3
44Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003592Phase 3
45Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During SurgeryCompletedNCT00002670Phase 3
46Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003888Phase 3
47Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck CancerCompletedNCT00006481Phase 3
48Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryCompletedNCT00424255Phase 3
49Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and NeckCompletedNCT00193895Phase 3
50Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck CancerCompletedNCT00273546Phase 3

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck


Cochrane evidence based reviews: carcinoma, squamous cell of head and neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

About this section

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

id Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck26

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

35
Lung, Thyroid, Skin, Lymph node, Salivary gland, Testes, Brain

Animal Models for Squamous Cell Carcinoma, Head and Neck or affiliated genes

About this section

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

40 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537010.2CD44, CDKN2A, CXCL14, EGFR, PTEN, STAT3
2MP:000538010.2CDH1, CDKN2A, CTTN, EGFR, PIK3CA, PTEN
3MP:000301210.1CDH1, CDKN2A, CTTN, CXCL14, EGFR, PIK3CA
4MP:000536910.1CD44, CDKN2A, EGFR, MMP2, MMP9, PIK3CA
5MP:000287310.0CCND1, CD44, CDH1, EGFR, MMP2, PTEN
6MP:000538810.0CCND1, CD44, CDKN2A, CTTN, EGFR, MMP2
7MP:000537910.0CCND1, CD44, CDH1, CDKN2A, EGFR, ING1
8MP:00053909.9CCND1, CD44, CDKN2A, EGFR, MMP2, MMP9
9MP:00107719.9CCND1, CD44, CDH1, CDKN2A, EGFR, MMP9
10MP:00053919.8CCND1, CD44, CDKN2A, EGFR, MMP2, MMP9
11MP:00053679.8CD44, CXCL14, EGFR, MMP9, PTEN, STAT3
12MP:00020069.8CCND1, CD44, CDH1, CDKN2A, EGFR, ING1
13MP:00053899.8CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
14MP:00053849.8CCND1, CD44, CDH1, CDKN2A, CTTN, EGFR
15MP:00053869.7CCND1, CD44, CDKN2A, CXCL14, ING1, MMP9
16MP:00036319.6CCND1, CD44, CDKN2A, EGFR, MMP2, MMP9
17MP:00053979.6CCND1, CD44, CDKN2A, CTTN, CXCL14, EGFR
18MP:00053879.5CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
19MP:00107689.4CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
20MP:00053819.4CCND1, CD44, CDH1, CDKN2A, EGFR, MMP9
21MP:00053789.3CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
22MP:00053769.3CCND1, CD44, CDH1, CDKN2A, CXCL14, EGFR
23MP:00053859.3CCND1, CD44, CDH1, CDKN2A, CTTN, EGFR

Publications for Squamous Cell Carcinoma, Head and Neck

About this section

Variations for Squamous Cell Carcinoma, Head and Neck

About this section

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

69
id Symbol AA change Variation ID SNP ID
1ING1p.Ala335AspVAR_017420
2ING1p.Cys358SerVAR_017421
3ING1p.Asn359SerVAR_017422
4ING3p.Asp20GlyVAR_021263
5PTENp.Ala121GlyVAR_018103rs121909237

Clinvar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

5 (show all 11)
id Gene Variation Type Significance SNP ID Assembly Location
1EGFRNM_005228.4(EGFR): c.2327G> A (p.Arg776His)SNVdrug responsers483352806GRCh37Chr 7, 55249029: 55249029
2EGFRNM_005228.4(EGFR): c.2471G> A (p.Gly824Asp)SNVdrug responsers483352808GRCh38Chr 7, 55191720: 55191720
3EGFRNM_005228.4(EGFR): c.2188C> G (p.Leu730Val)SNVdrug responsers121913434GRCh37Chr 7, 55242418: 55242418
4EGFRNM_005228.4(EGFR): c.2393T> A (p.Leu798His)SNVdrug responsers483352807GRCh38Chr 7, 55181402: 55181402
5EGFRNM_005228.4(EGFR): c.2176G> A (p.Val726Met)SNVdrug responsers483352805GRCh37Chr 7, 55241728: 55241728
6EGFRNM_005228.4(EGFR): c.2155G> C (p.Gly719Arg)SNVLikely pathogenic, drug responsers28929495GRCh37Chr 7, 55241707: 55241707
7TNFRSF10BTNFRSF10B, 2-BP INSinsertionPathogenicChr na, -1: -1
8PTENNM_000314.6(PTEN): c.362C> G (p.Ala121Gly)SNVPathogenicrs121909237GRCh37Chr 10, 89692878: 89692878
9ING1NM_198217.2(ING1): c.512G> C (p.Cys171Ser)SNVPathogenicrs121909250GRCh37Chr 13, 111372083: 111372083
10ING1NM_198217.2(ING1): c.515A> G (p.Asn172Ser)SNVPathogenicrs121909251GRCh37Chr 13, 111372086: 111372086
11ING1NM_198217.2(ING1): c.443C> A (p.Ala148Asp)SNVPathogenicrs121909252GRCh37Chr 13, 111372014: 111372014

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

8 (show top 50)    (show all 376)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM14452PTCH1skin,neck,carcinoma,NSc.2321G>Ap.G774E48
2COSM29072PTCH1skin,neck,carcinoma,NSc.1067+1G>Ap.?48
3COSM29053PTCH1skin,neck,carcinoma,NSc.833G>Ap.W278*48
4COSM498HRASskin,neck,carcinoma,squamous cell carcinoma BRAF inhibitor relatedc.182A>Tp.Q61L48
5COSM516KRASskin,neck,carcinoma,NSc.34G>Tp.G12C48
6COSM17483PTCH1skin,neck,carcinoma,NSc.1729-1G>Tp.?48
7COSM17468PTCH1skin,neck,carcinoma,NSc.584G>Tp.R195M48
8COSM6240EGFRupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2369C>Tp.T790M38
9COSM99622NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.4016G>Cp.G1339A38
10COSM44310TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.738G>Ap.M246I38
11COSM10648TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.524G>Ap.R175H38
12COSM11196TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.734G>Tp.G245V38
13COSM763PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1633G>Ap.E545K38
14COSM24802FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2089G>Tp.G697C38
15COSM33692HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.185A>Gp.E62G38
16COSM43947TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.614A>Gp.Y205C38
17COSM44393TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.821T>Cp.V274A38
18COSM764PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1634A>Gp.E545G38
19COSM43582TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.454C>Tp.P152S38
20COSM483HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Tp.G12V38
21COSM29446FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.753C>Tp.H251H38
22COSM44226TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.380C>Tp.S127F38
23COSM99653NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.3835C>Tp.R1279C38
24COSM10654TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.637C>Tp.R213*38
25COSM10704TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.844C>Tp.R282W38
26COSM10672TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.577C>Tp.H193Y38
27COSM10941TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.730G>Ap.G244S38
28COSM10656TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.742C>Tp.R248W38
29COSM10728TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.839G>Ap.R280K38
30COSM43635TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.536A>Tp.H179L38
31COSM1667029NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.666C>Ap.C222*38
32COSM44126TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.507G>Ap.M169I38
33COSM10790TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.455C>Tp.P152L38
34COSM43868TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.689C>Tp.T230I38
35COSM12504CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.247C>Tp.H83Y38
36COSM44335TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.958A>Tp.K320*38
37COSM44091TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.746G>Ap.R249K38
38COSM11063TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Tp.M237I38
39COSM1737921CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.124A>Cp.N42H38
40COSM44577TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.921A>Gp.A307A38
41COSM3722007HCN1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.808C>Tp.R270*38
42COSM488HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.37G>Tp.G13C38
43COSM99939NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.5529G>Ap.W1843*38
44COSM10834TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Ap.M237I38
45COSM45099TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.924G>Ap.L308L38
46COSM3724382NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.6738C>Gp.H2246Q38
47COSM521KRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Ap.G12D38
48COSM3724387CASP8upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.415C>Tp.Q139*38
49COSM480HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Ap.G12S38
50COSM481HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Tp.G12C38

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

6 (show all 42)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
13395215070000061300000Amplificationhead and neck squamous cell carcinoma
271135126770000071500000Amplificationhead and neck squamous cell carcinoma
378639135530000073300000Amplificationhead and neck squamous cell carcinoma
490904152570000028100000Amplificationhead and neck squamous cell carcinoma
593784155910000059300000Copy numberMEThead and neck squamous cell carcinoma
61180061775058217531588LOHTP53head and neck squamous cell carcinoma
71191921817100000Amplificationhead and neck squamous cell carcinoma
8119790181720000019000000Amplificationhead and neck squamous cell carcinoma
91661343187900000Losshead and neck squamous cell carcinoma
101676353121900000167600000Gainhead and neck squamous cell carcinoma
111695563142800000148900000Amplificationhead and neck squamous cell carcinoma
121714863168801287168851758AmplificationEVI1head and neck squamous cell carcinoma
131714953168867391169381563AmplificationMDS1head and neck squamous cell carcinoma
141724873182700000187900000AmplificationRFC4head and neck squamous cell carcinoma
151747461277732777793336DeletionDLEChead and neck squamous cell carcinoma
16179443391000000121900000Gainhead and neck squamous cell carcinoma
171799734150400000Losshead and neck squamous cell carcinoma
182047366114600000171115067Gainhead and neck squamous cell carcinoma
1921704971159138663Copy numberhead and neck squamous cell carcinoma
2022536974540000054000000GainEGFRhead and neck squamous cell carcinoma
2122538374540000054000000AmplificationEGFRhead and neck squamous cell carcinoma
2222540374540000054000000Copy numberEGFRhead and neck squamous cell carcinoma
2322540474540000054000000Copy numberEGFRhead and neck squamous cell carcinoma
2422540874540000054000000Deletion or amplific ationEGFRhead and neck squamous cell carcinoma
2522541374540000058000000Amplificationhead and neck squamous cell carcinoma
2622653275800000059900000Amplificationhead and neck squamous cell carcinoma
272327478119200000122500000GainMYChead and neck squamous cell carcinoma
282337698127300000139900000GainKHDRBS3head and neck squamous cell carcinoma
292348768139900000146364022GainFAKhead and neck squamous cell carcinoma
302348958139900000146364022GainPTP4A3head and neck squamous cell carcinoma
3123801182880000045600000Amplificationhead and neck squamous cell carcinoma
3223998884310000045600000Amplificationhead and neck squamous cell carcinoma
33240109845600000146364022GainGAA1head and neck squamous cell carcinoma
3424189986800000070500000Amplificationhead and neck squamous cell carcinoma
35243677886900000101600000AmplificationRUNX1T1head and neck squamous cell carcinoma
3624998491990000025500000DeletionCDKN2Ahead and neck squamous cell carcinoma
37300518119535108795715992MethylationMAML2head and neck squamous cell carcinoma
3830053012123374913123617963MethylationNCOR2head and neck squamous cell carcinoma
39300892147267293172756862MethylationPSEN1head and neck squamous cell carcinoma
40300893147281167072995039MethylationNUMBhead and neck squamous cell carcinoma
41302931194586365145888396MethylationNUMBLhead and neck squamous cell carcinoma
42303261201056633110602694MethylationJAG1head and neck squamous cell carcinoma

Expression for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 34 (show all 15)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1MMP1matrix metallopeptidase 1Head Mesenchyme+5.250.000
2TMPRSS11Btransmembrane protease, serine 11BHead Mesenchyme-4.810.000
3CRISP3cysteine-rich secretory protein 3Head Mesenchyme-4.480.000
4MALmal, T-cell differentiation proteinHead Mesenchyme-4.390.000
5INHBAinhibin, beta AHead Mesenchyme+4.130.000
6CRNNcornulinHead Mesenchyme-4.000.000
7KRT17keratin 17, type IHead Mesenchyme+3.940.000
8KRT4keratin 4, type IIHead Mesenchyme-3.410.000
9PTHLHparathyroid hormone-like hormoneHead Mesenchyme+3.360.000
10CTHRC1collagen triple helix repeat containing 1Head Mesenchyme+3.320.000
11CLCA4chloride channel accessory 4Head Mesenchyme-3.310.000
12WDR72WD repeat domain 72Head Mesenchyme+3.230.000
13MMP10matrix metallopeptidase 10Head Mesenchyme+3.140.001
14TGM3transglutaminase 3Head Mesenchyme-3.080.000
15GBP1guanylate binding protein 1, interferon-inducibleHead Mesenchyme+3.060.000

Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 44)
idSuper pathwaysScoreTop Affiliating Genes
110.2CCND1, STAT3, VEGFA
210.2CCND1, CDH1, TP53
310.2EGFR, PIK3CA, STAT3
410.2CDH1, EGFR, PIK3CA
510.2CDH1, EGFR, PIK3CA
610.2CCND1, MMP2, MMP9
7
Show member pathways
10.2MMP9, PIK3CA, VEGFA
810.2CCND1, EGFR, PTEN, STAT3
910.2MMP2, MMP9, PIK3CA
1010.2EGFR, PIK3CA, PTEN, TP53
1110.2CCND1, PIK3CA, PTEN, TP53
1210.2CCND1, EGFR, MMP9, TP53
1310.1EGFR, PIK3CA, STAT3, TP53
14
Show member pathways
10.1EGFR, PIK3CA, STAT3, TP53
1510.1EGFR, PIK3CA, STAT3, VEGFA
1610.1EGFR, PIK3CA, STAT3, VEGFA
1710.1EGFR, MMP2, MMP9, STAT3
1810.1CD44, EGFR, MMP2, MMP9
1910.1CCND1, CDH1, CTTN, PIK3CA
2010.1CCND1, CDKN2A, EGFR, PTEN, TP53
2110.1CCND1, CDH1, MMP2, MMP9
2210.1EGFR, MMP2, PTEN, TNFRSF10B, TP53
2310.1CD44, CDH1, MMP2, MMP9
2410.1CDH1, CTTN, MMP9, PIK3CA
25
Show member pathways
10.1CD44, MMP2, MMP9, PIK3CA
26
Show member pathways
10.1CCND1, EGFR, PIK3CA, PTEN, STAT3
27
Show member pathways
10.1CCND1, EGFR, PIK3CA, STAT3, TP53
2810.1CCND1, CDKN2A, PIK3CA, STAT3, TP53
2910.0CCND1, MMP2, PIK3CA, STAT3, VEGFA
3010.0CCND1, CDH1, EGFR, PTEN, TP53, VEGFA
3110.0CD44, CDKN2A, CXCL14, ING1, PTEN, TP53
3210.0CCND1, EGFR, PIK3CA, PTEN, TP53, VEGFA
3310.0CCND1, EGFR, PIK3CA, PTEN, TP53, VEGFA
34
Show member pathways
10.0CCND1, EGFR, MMP2, PIK3CA, PTEN, STAT3
35
Show member pathways
10.0CDH1, PIK3CA, PTEN, STAT3, TP53, VEGFA
36
Show member pathways
9.9CCND1, CDH1, CDKN2A, EGFR, PIK3CA, PTEN
37
Show member pathways
9.9CCND1, CDKN2A, EGFR, PIK3CA, STAT3, TP53
38
Show member pathways
9.9CCND1, CDH1, EGFR, PIK3CA, PTEN, STAT3
39
Show member pathways
9.8CCND1, EGFR, MMP2, MMP9, PIK3CA, PTEN
409.8CCND1, CDH1, CDKN2A, EGFR, MMP2, MMP9
419.8CCND1, CDH1, EGFR, MMP2, MMP9, STAT3
429.7CCND1, CD44, CDKN2A, EGFR, MMP9, PIK3CA
439.6CCND1, CD44, CTTN, EGFR, MMP2, MMP9
449.6CCND1, CDH1, CDKN2A, EGFR, MMP2, MMP9

GO Terms for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1response to UV-AGO:007014111.0CCND1, EGFR
2response to leptinGO:004432110.9CCND1, STAT3
3mitotic G1 DNA damage checkpointGO:003157110.9CCND1, TP53
4regulation of mitochondrial membrane permeabilityGO:004690210.9STAT3, TP53
5replicative senescenceGO:009039910.9CDKN2A, TP53
6positive regulation of vascular smooth muscle cell proliferationGO:190470710.7MMP2, MMP9
7positive regulation of peptidyl-tyrosine phosphorylationGO:005073110.7CD44, TP53, VEGFA
8positive regulation of protein phosphorylationGO:000193410.6CCND1, EGFR, MMP9, VEGFA
9response to organic cyclic compoundGO:001407010.6CCND1, EGFR, PTEN, STAT3
10extracellular matrix disassemblyGO:002261710.6CD44, CDH1, MMP2, MMP9
11response to organic substanceGO:001003310.5CCND1, CDH1, PTEN, STAT3
12angiogenesisGO:000152510.4MMP2, PIK3CA, PTEN, VEGFA
13positive regulation of peptidyl-serine phosphorylationGO:003313810.4CD44, PIK3CA, VEGFA
14response to estradiolGO:003235510.2CCND1, EGFR, PTEN, STAT3
15negative regulation of apoptotic processGO:004306610.1CD44, EGFR, MMP9, PTEN, STAT3, TP53
16positive regulation of cell proliferationGO:000828410.1CCND1, EGFR, PTEN, STAT3, VEGFA
17cell proliferationGO:000828310.0EGFR, PTEN, RPS27, STAT3, TP53
18negative regulation of cell proliferationGO:00082859.8CDKN2A, ING1, PTEN, STAT3, TP53

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein phosphatase bindingGO:001990310.8EGFR, STAT3, TP53
2protein kinase bindingGO:001990110.3CCND1, CDKN2A, EGFR, PTEN, STAT3, TP53
3identical protein bindingGO:00428029.9EGFR, MMP9, PTEN, STAT3, TP53, VEGFA
4protein bindingGO:00055159.0CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14

Sources for Squamous Cell Carcinoma, Head and Neck

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet